NCT01424501View on ClinicalTrials.gov

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

November 14, 2011

Primary Completion Date

April 1, 2014

Study Completion Date

April 10, 2014

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GSK Biologicals' investigational TB vaccine GSK 692342

Intramuscular injection, 2 doses

BIOLOGICAL

Placebo

Intramuscular injection, 2 doses

Trial Locations (6)

100

GSK Investigational Site, Taipei

220

GSK Investigational Site, Taipei

333

GSK Investigational Site, Taoyuan Hsien

10117

GSK Investigational Site, Tallinn

51014

GSK Investigational Site, Tartu

Unknown

GSK Investigational Site, Taipei

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01424501 - Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease | Biotech Hunter | Biotech Hunter